Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 4, 2013, Pages 306-316

  Gitelman, Stephen E ^a   Gottlieb, Peter A ^b   Rigby, Mark R ^c   Felner, Eric I ^d   Willi, Steven M ^e   Fisher, Lynda K ^f   Moran, Antoinette ^g   Gottschalk, Michael ^h   Moore, Wayne V ⁱ   Pinckney, Ashley ^j   Keyes Elstein, Lynette ^j   Aggarwal, Sudeepta ^k   Phippard, Deborah ^k   Sayre, Peter H ^l   Ding, Linna ^m   Bluestone, Jeffrey A ^a   Ehlers, Mario R ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CHILDREN S MERCY HOSPITAL   (United States)

^j Rho Federal Systems Division Inc   (United States)

^k Immune Tolerance Network   (United States)

^l Immune Tolerance Network   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; SERUM AMYLOID A; THYMOCYTE ANTIBODY; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIBODY;

ACNE; ADOLESCENT; ADULT; AGE DISTRIBUTION; APPENDICITIS; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BACKACHE; BIPOLAR DISORDER; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CHILD; CLINICAL ARTICLE; COMMINUTED FRACTURE; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EXFOLIATIVE RASH; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOPENIA; MAJOR DEPRESSION; MALE; MEDIASTINUM DISEASE; MEMORY T LYMPHOCYTE; METABOLIC DISORDER; MONOTHERAPY; MOOD CHANGE; MOOD DISORDER; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; OROPHARYNX PAIN; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECENT ONSET TYPE 1 DIABETES; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; RHINORRHEA; SCHOOL CHILD; SERUM SICKNESS; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS TISSUE DISORDER; SUBSTANCE ABUSE; T CELL DEPLETION; THORAX DISEASE; TREATMENT DURATION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VIRAL GASTROENTERITIS; VIRUS INFECTION; VOMITING; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887624109     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70065-2     Document Type: Article

References (28)

1. Imperatore G, Boyle JP, Thompson TJ, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012, 35:2515-2520. the SEARCH for Diabetes in Youth Study Group.
2. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373:2027-2033. the EURODIAB Study Group.
3. Bluestone JA, Herold K, Eisenbarth G Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
4. Steffes MW, Sibley S, Jackson M, Thomas W Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832-836.
5. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988, 37:1574-1582. The Canadian-European Randomized Control Trial Group.
6. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2:119-124.
7. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419. the Type 1 Diabetes TrialNet Abatacept Study Group.
8. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
9. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497. the Protégé Trial Investigators.
10. Herold KC, Gitelman S, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, published online July 8. 10.2337/db13-0345.
11. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010, 70:691-732.
12. Simon G, Parker M, Ramiya V, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 2008, 57:405-414.
13. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003, 361:1502-1510.
14. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000, 37:69-80.
15. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985, 2:271-276.
16. Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004, 1:80-88.
17. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301:1573-1579.
18. Li L, Shen S, Ouyang J, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 2012, 97:1729-1736.
19. Snarski E, Milczarczyk A, Torosian T, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011, 46:562-566.
20. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012, 61:2340-2348. the Diabetes TrialNet and the Immune Tolerance Network.
21. Lachin JM, McGee PL, Greenbaum CJ, et al. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One 2011, 6:e26471. the Type 1 Diabetes Trial Network.
22. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152. the Type 1 Diabetes TrialNet Anti-CD20 Study Group.
23. Neurath MF, Finotto S IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
24. Préville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001, 71:460-468.
25. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010, 10:2132-2141.
26. Huang Y, Parker M, Xia C, et al. Rabbit polyclonal mouse antithymocyte globulin administration alters dendritic cell profile and function in NOD mice to suppress diabetogenic responses. J Immunol 2009, 182:4608-4615.
27. Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007, 13:647-650.
28. Parker MJ, Xue S, Alexander JJ, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009, 58:2277-2284.